Navigation Links
CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
Date:4/24/2008

LAS VEGAS, April 24 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBTE) has entered into an agreement with Mr. Phillip Frey Jr. to form Cardio Derma Clinical Partners (CDCP), an R&D Partnership. Mr. Frey, as sponsor and general partner, will fund a minimum of $1,000,000 and up to $5,000,000 of the clinical development of CVBT's wound healing drug candidate.

"R&D Partnerships have been successfully used in the past by some of today's biggest names in biotechnology to fund drug development. Many investors in these R&D Partnerships realized income tax advantages and have earned outstanding returns on their investments," said Mr. Phillip Frey Jr. He continued, "CVBT and Cardio Derma Clinical Partners are going back to these basics in an effort to advance this drug candidate."

CDCP will engage CVBT in a development agreement to conduct its wound healing clinical trial. CVBT will pay a royalty to CDCP of 10% of revenues or other moneys received from the commercialization of the drug candidate up to a maximum of ten times (10x) the funded amount of the development agreement in return for the intellectual property created. Additionally, CDCP will acquire warrants, the number of which is dependent upon the funded amount of the development agreement, to purchase CVBT common shares at an exercise price of $1.00 per share with a term of five years. Daniel C. Montano, CVBT's President and CEO, has agreed to personally provide the individual partners of CDCP a Put to Mr. Montano for their interest in CDCP equal to 200% of their investment in CDCP less distributions paid from CDCP commencing 36 months and ending 60 months after their investment in CDCP.

CVBT's pipeline includes drug candidates for the treatment of various cardiovascular diseases, including severe coronary heart disease, diabetic wounds, peripheral arterial disease, chronic back pain and bone repair. "We anticipate knowing whether we will meet the e
'/>"/>

SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
2. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
3. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
4. HealthAware Introduces Its VascularAware Cardiovascular Disease Module
5. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
6. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
7. VIA Pharmaceuticals Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Informations Therapeutic Area Partnerships Conference
8. Amarin Announces Initiation of Cardiovascular Development Strategy
9. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
10. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
11. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ICAGO, Nov. 30 Dr. Jessica Torrent...ington University Medical Center in Washington, D....-Specific Gamma Imaging (BSGI) in clinical practic... of breast cancer today at the annual meeting of t..., "The purpose of the exhibit was to demonstrat...
(Date:11/30/2009)..., SEATTLE, Nov. 30 Ce... announced today that its new class of platinum-ba...emonstrated a stronger anti-tumor potency and acti...d compounds as well as the ability to overcome cis...ts were presented in a paper titled "Novel Bis-pla...
(Date:11/29/2009)...se is available in German . , The concept o...n physics. The most famous example is that of quar...s. Now Prof. Bella Lake from Helmholtz-Zentrum Ber...sts report for the first time an experimental real...rved in a condensed matter system. , The concept...
(Date:11/26/2009)...FAYETTE, Ind. - A new generation of ultrasmall tra...ny structures called semiconducting nanowires are ...hers at IBM, Purdue University and the University ...have learned how to create nanowires with layers o...the atomic level, which is a critical requirement ...
Breaking Biology Technology:Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3Spinons -- confined like quarks 2Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3
...., Feb. 20 InterMune, Inc. (Nasdaq: ITMN ) anno...d full-year 2008 financial results on Thursday, Fe... conference call and webcast will be hosted by Int... , To access the live teleconference, dial 888-79...ference ID# 86755415. To access the webcast, plea...
...The Netherlands, February 20 Nyenrode Business,Un...to Professor Michael,Porter, icon in the field of ...heory. Professor Porter is generally considered as...e world,s most influential thought leader in the,f...ssor Porter will receive,the Honorary Doctorate on...
...fety Study in Patients with Severe Post-Operative ...its and Support NDA Submission , , SYDNEY and BED...X and OTCQX: QRXPY), a clinical-stage specialty ph...d commercialisation of therapies for pain and cent...y the initiation of a comparative 3-arm pilot stud...
Other Biology Technology:InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26 2Nyenrode Honorary Doctorate for Professor Michael E. Porter 2QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy 2QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy 3QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy 4
(Date:11/30/2009)...a colorless and odorless radioactive gas that is p... is a product of uranium decay and is found in tra...nd groundwater as well as building materials, plan...tration is expressed as the amount of radiation th...s in a liter of air; thus the units are picocuries...
(Date:11/26/2009)...have at last worked out a way of using recordings ... populations. This is the first time sound recordi...nto accurate estimates of bird species, population...ish Ecological Society,s Journal of Applied Ecolo... to a major advance in our ability to monitor whal...
(Date:11/26/2009)...erg, 27 November 2009 What are the bare essential...to produce a cell that can survive on its own? Can...understand how an entire organism functions as a s...cientists in a partnership between the European Mo...ermany, and the Centre de Regulacio Genmica (CRG) ...
Breaking Biology News(10 mins):Health Physics Society recommends considering action for indoor radon below current guidelines 2Ecologists sound out new solution for monitoring cryptic species 2First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting Edge Treatment to Satellite Communities 56758 1New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting Edge Treatment to Satellite Communities 56758 2New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting Edge Treatment to Satellite Communities 56758 3New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting Edge Treatment to Satellite Communities 56758 4New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting Edge Treatment to Satellite Communities 56758 5Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 13979 1Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 13979 2Video 3A U S Department of Health and Human Services Joins Ad Council and Warner Bros Pictures to Combat Childhood Overweight and Obesity 56755 1Video 3A U S Department of Health and Human Services Joins Ad Council and Warner Bros Pictures to Combat Childhood Overweight and Obesity 56755 2Video 3A U S Department of Health and Human Services Joins Ad Council and Warner Bros Pictures to Combat Childhood Overweight and Obesity 56755 3Video 3A U S Department of Health and Human Services Joins Ad Council and Warner Bros Pictures to Combat Childhood Overweight and Obesity 56755 4Video 3A U S Department of Health and Human Services Joins Ad Council and Warner Bros Pictures to Combat Childhood Overweight and Obesity 56755 5
...are the first to create a large-scale, cell-based ...ctivate immune-response cells that hold promise fo...ning technique can scan thousands and even million...dritic cells, which are on constant recon patrol t...ted cells and alert the immune system. , "Our ass...
...itoes that helps the insects to fight off infectio... in humans. Anopheles mosquitoes transmit the mala...e each year with these cases resulting in more tha...as identified in a study conducted by a team of in...l of Public Health,s Malaria Research Institute, t...
...ia, private practice, government and industry are ... symposium in interventional oncology, a rapidly g...ve interventional radiology treatments for cancer....tments for liver, kidney, bone and lung tumors. Th...ty for cross-fertilization between researchers in ...
Other Biology News:UT Southwestern researchers develop screening test for cells that activate immune system 2Gene that helps mosquitoes fight off malaria parasite identified 2Minimally Invasive Cancer Treatments Highlighted 2Minimally Invasive Cancer Treatments Highlighted 3
Mouse Anti-JNK2 Antibody, Unconjugated from Upstate
...: Synthetic peptide derived from the C-terminal re...ase C zeta isoform (PKCzeta). Specificity: Reacts...es PKCzeta and PKMzeta (PKCzeta II) and does not c... Rat (positive controls: mouse and rat kidney and ...
GIBCO AlbuMAX II from Invitrogen
GIBCO Dulbecco's Phosphate-Buffered Saline (D-PBS) (1X) liquid from Invitrogen
Biology Products: